Revenue growth and slight profit growth in the Life Sciences business
First written in FY2019-Q3. . Latest entry: 2026-09-16.
No other company in this theme has enough history to compare yet.
- 2026-09-16Otherfinance.yahoo.co.jpShipment delays for DDS pharmaceutical formulation ingredients related to the pharmaceutical, medical and healthcare sectors, as well as a decline in quarterly profit, were reported.
- 2026-08-05OtherEarnings
「As a result, net sales in the pharmaceutical, medical and healthcare business amounted to ¥11,244 million, down 17.9% year on year, while operating profit was ¥1,223 million, down 77.6%.」
The pharmaceutical, medical and healthcare business reported lower revenue and profit in the first quarter. - FY2026Full-Year Results Updated; Revenue and Profit UpAnnual report
「As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥49,931 million, up 4.0% year on year, and operating profit was ¥15,816 million, up 0.8%.」
The Pharmaceuticals, Medical and Healthcare business, renamed from the Life Sciences business, posted higher revenue and profit for the full year. Increased shipments for health food products and the maintenance of appropriate prices contributed. - FY2026-H1Updated to first-half results; higher revenue and profitAnnual report
「As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥24,999 million, up 8.5% year on year, and operating profit was ¥8,360 million, up 3.4%.」
The Pharmaceuticals, Medical and Healthcare business posted higher revenue and profit in the current interim period. Increased shipments for health food products and the maintenance of appropriate prices for edible processed oils and fats and functional food materials contributed. - FY2025Full-year results updated; lower revenue and profitAnnual report
「As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥48,033 million, down 11.0% year on year, and operating profit was ¥15,697 million, down 23.6%.」
The Pharmaceuticals, Medical and Healthcare business, renamed from the former Life Sciences business, posted lower revenue and profit for the full year. Inventory adjustments for some customers and lower demand for DDS pharmaceutical formulation ingredients due to monetary tightening in Europe and the United States affected results. - FY2025-H1Updated to first-half results; lower revenue and profitAnnual report
「As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥23,046 million, down 12.7% year on year, and operating profit was ¥8,082 million, down 23.0%.」
The Pharmaceuticals, Medical and Healthcare business recorded lower revenue and profit in the first half. The disclosures cite inventory adjustments for some customers and lower demand for DDS pharmaceutical formulation ingredients due to monetary tightening in Europe and the United States. - FY2024Full-year results updated; higher revenue and profit continuedAnnual report
「As a result, consolidated revenue from the Pharmaceuticals, Medical and Healthcare business was ¥53,998 million, up 5.1% year on year, and consolidated operating profit was ¥20,558 million, up 12.9%.」
The Pharmaceuticals, Medical and Healthcare business, renamed from the Life Sciences business, posted higher revenue and profit for the full year. Shipments for health food products and shipments of DDS pharmaceutical formulation ingredients to Europe and the United States increased. - FY2024-Q3Updated to third-quarter results; higher revenue and profit continuedAnnual report
「As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥41,675 million, up 9.2% year on year, and operating profit was ¥16,927 million, up 23.6%.」
The Pharmaceuticals, Medical and Healthcare business, renamed from the Life Sciences business, posted higher revenue and profit on a cumulative third-quarter basis. Increased shipments for health food products and increased shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2024-Q2Update to first-half results after the segment name change, higher operating profitAnnual report
「As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥26,410 million, unchanged year on year, and operating profit was ¥10,498 million, up 7.6%.」
The Pharmaceuticals, Medical and Healthcare business, renamed from the Life Sciences business, recorded revenue broadly in line with the same period of the previous year and higher operating profit in the first half. - FY2024-Q1Update to first-quarter results after the segment name change, lower revenue and profitAnnual report
「From the current fiscal year, the name of the reporting segment previously presented as the Life Sciences business has been changed to the Pharmaceuticals, Medical and Healthcare business. As a result, revenue from the Pharmaceuticals, Medical and Healthcare business was ¥13,751 million, down 4.6% year on year, and operating profit was ¥5,831 million, down 13.9%.」
The Life Sciences business was renamed the Pharmaceuticals, Medical and Healthcare business, and comparative figures after the segment classification change were disclosed. The business recorded lower revenue and profit in the first quarter. - FY2023-Q3Updated to third-quarter results; higher revenue and profit continuedAnnual report
「As a result, revenue from the Life Sciences business was ¥31,128 million, up 17.9% year on year, and operating profit was ¥13,762 million, up 14.0%.」
The Life Sciences business posted higher revenue and profit on a cumulative third-quarter basis. Demand for MPC-related products and shipments of DDS pharmaceutical formulation ingredients to Europe and the United States were strong. - FY2023-Q2Updated to first-half results; higher revenue and profit continuedAnnual report
「As a result, revenue from the Life Sciences business was ¥21,158 million, up 23.6% year on year, and operating profit was ¥9,603 million, up 16.4%.」
The Life Sciences business posted higher revenue and profit in the first half. Strong demand for MPC-related products and strong shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2023-Q1Updated to first-quarter results; higher revenue and profit continuedAnnual report
「As a result, revenue from the Life Sciences business was ¥12,156 million, up 70.1% year on year, and operating profit was ¥6,898 million, up 105.9%.」
The Life Sciences business posted substantial increases in revenue and profit in the first quarter. Strong demand for MPC-related products and strong shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2022Full-year results updated; higher revenue and profit continuedAnnual report
「As a result, consolidated revenue from the Life Sciences business was ¥33,745 million, compared with ¥31,232 million in the same period of the previous year, while consolidated operating profit was ¥14,109 million, compared with ¥10,310 million.」
The Life Sciences business posted higher revenue and profit for the full year. Strong shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2022-Q3Updated to third-quarter results; higher revenue and profitAnnual report
「As a result, revenue from the Life Sciences business was ¥26,382 million, compared with ¥23,133 million in the same period of the previous year, while operating profit was ¥12,066 million, compared with ¥7,411 million.」
The Life Sciences business posted higher revenue and profit on a cumulative third-quarter basis. Shipments of DDS pharmaceutical formulation ingredients to Europe and the United States were strong. - FY2022-Q2Updated to first-half results; higher revenue and profitAnnual report
「As a result, revenue from the Life Sciences business was ¥17,121 million, compared with ¥14,564 million in the same period of the previous year, while operating profit was ¥8,247 million, compared with ¥4,148 million. The adoption of the revenue recognition accounting standards and related changes had a negative impact of ¥339 million on revenue and a positive impact of ¥89 million on profit.」
The Life Sciences business posted higher revenue and profit in the first half. Strong shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2022-Q1Update to first-quarter results, lower revenue and higher profitAnnual report
「As a result, revenue from the Life Sciences business was ¥7,147 million, compared with ¥7,276 million in the same period of the previous year, while operating profit was ¥3,349 million, compared with ¥2,164 million.」
The Life Sciences business recorded lower revenue in the first quarter, while operating profit increased. Strong demand for MPC-related products and strong shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2021Full-year results updated; higher revenue and profit continuedAnnual report
「As a result, consolidated revenue from the Life Sciences business was ¥31,232 million, up 2.8% year on year, and consolidated operating profit was ¥10,310 million, up 21.9%.」
The Life Sciences business posted higher revenue and profit for the full year, supported by increased demand for and shipments of MPC-related products and DDS pharmaceutical formulation ingredients. - FY2021-Q3Update to third-quarter results, with higher revenue and profit continuingAnnual report
「As a result, revenue from the Life Sciences business was ¥23,133 million, up 2.2% year on year, and operating profit was ¥7,411 million, up 29.4%.」
The Life Sciences business posted higher revenue and profit on a cumulative third-quarter basis. Strong demand for MPC-related products and strong shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2021-Q2Update to first-half results, lower revenue and higher profitAnnual report
「As a result, revenue from the Life Sciences business was ¥14,564 million, down 1.6% year on year, while operating profit was ¥4,148 million, up 14.4%, due to the product mix.」
The Life Sciences business recorded lower revenue in the first half, while operating profit increased due to the product mix. Increased demand for and shipments of MPC-related products and DDS pharmaceutical formulation ingredients are noted. - FY2021-Q1Update to first-quarter results, lower revenue and higher profitAnnual report
「As a result, revenue from the Life Sciences business was ¥7,276 million, down 1.5% year on year, while operating profit was ¥2,164 million, up 15.7%, partly due to the product mix.」
The Life Sciences business recorded lower revenue in the first quarter, while operating profit increased 15.7% year on year. It notes increased demand for and shipments of MPC-related products and DDS pharmaceutical formulation ingredients. - FY2020Full-year results updated; higher revenue and profitAnnual report
「As a result, consolidated revenue from the Life Sciences business was ¥30,369 million, up 9.2% year on year, and consolidated operating profit was ¥8,456 million, up 14.4%.」
The Life Sciences business posted higher revenue and profit for the full year, supported by increased demand for and shipments of MPC-related products and DDS pharmaceutical formulation ingredients. - FY2020-Q3Update to third-quarter resultsAnnual report
「As a result, revenue from the Life Sciences business was ¥22,635 million, up 9.3% year on year, and operating profit was ¥5,727 million, up 29.7%.」
The Life Sciences business posted higher revenue and profit on a cumulative nine-month basis. Increased shipments of DDS pharmaceutical formulation ingredients to Europe and the United States contributed. - FY2020-Q2Updated to first-half resultsAnnual report
「As a result, revenue from the Life Sciences business was ¥14,798 million, up 7.5% year on year, and operating profit was ¥3,626 million, up 25.1%.」
The Life Sciences business posted higher revenue and profit in the first half, with operating profit increasing 25.1% year on year. - FY2020-Q1Updated to first-quarter resultsAnnual report
「As a result, revenue from the Life Sciences business was ¥7,389 million, up 14.1% year on year, and operating profit was ¥1,871 million, up 70.9%, partly due to the product mix.」
The Life Sciences business recorded higher revenue in the first quarter, while operating profit also increased 70.9% year on year. - FY2019Update to full-year resultsAnnual report
「As a result, consolidated revenue from the Life Sciences business was ¥27,814 million, up 1.4% year on year, and consolidated operating profit was ¥7,388 million, up 2.4%.」
The Life Sciences business posted higher revenue and profit for the full year. Shipments of DDS pharmaceutical formulation ingredients to major customers in Europe and the United States increased. - FY2019-Q3First statedAnnual report
「As a result, revenue from the Life Sciences business was ¥20,716 million, up 3.3% year on year, and operating profit was ¥4,416 million, up 0.6%.」
It states that demand for edible processed oils and fats and DDS pharmaceutical formulation ingredients increased, while demand for functional food-related products and biocompatible materials declined.